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Assessment of Minimal Residual Disease  
in Standard-Risk AML
To the Editor: Ivey and colleagues (Feb. 4 issue)1 
tested the prognostic value of the presence of a 
mutation in the gene encoding nucleophosmin 
(NPM1) in patients with acute myeloid leukemia 
(AML) who were in complete hematologic remis-
sion after a second cycle of chemotherapy,2 al-
though the recovery of cell counts in peripheral 
blood was not required for a determination of 
such remission. Some of the patients were in re-
mission after the first cycle of chemotherapy and 
some were not. Moreover, some of the patients in 
remission had normal blood counts and some 
did not. Other studies have shown the prognostic 
importance of obtaining normal blood counts 
over shorter durations of time and with fewer 
cycles required to achieve remission. Thus, we 
wonder whether the patients who did not have 
minimal residual disease were more likely to 
have a remission with normal cell counts and 
more likely to be in remission after the first cycle 
of chemotherapy than were patients who were 
found to have minimal residual disease.
Michele Baccarani, M.D.
University of Bologna 
Bologna, Italy 
michele . baccarani@ unibo . it
No potential conflict of interest relevant to this letter was re-
ported.
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To the Editor: Ivey et al. describe the persis-
tence of mutations in genes other than NPM1 in 
the blood and marrow of patients with AML 
who were in complete hematologic remission. 
The authors also state that patients with persis-
tent NPM1 transcripts (the presence of which 
defined minimal residual disease) had a worse 
prognosis than those who did not carry this 
marker and that virtually all patients who had a 
relapse carried the NPM1 mutation. At our center, 
in 32 consecutive patients (median age, 55 years) 
with cytogenetically normal AML carrying a de 
novo mutation in NPM1 without internal tan-
dem duplications in the gene encoding Fms-like 
tyrosine kinase 3 (FLT3-ITD) who had a com-
plete remission after intensive chemotherapy, 
14 (44%) had a relapse (all with the same NPM1 
mutation as the one observed at diagnosis), 12 
(38%) remained in complete remission, and 6 (19%) 
(all of whom were >55 years of age) had disease 
that developed into either the myelodysplastic 
syndrome (in 5 patients) or primary myelofibro-
sis (in 1 patient) (Fig. 1A). In each of these 6 pa-
tients, a preleukemic clone with at least one 
mutation in TET2, JAK2, ASXL1, IDH2, or a gene 
encoding a spliceosome protein was found at 
the time of the AML diagnosis and was present 
after the development of either the myelodys-
plastic syndrome or primary myelofibrosis (Fig. 
1B). However, the NPM1 mutation was absent. 
Thus, although we agree that relapse does not 
arise from preleukemic clones of cells with 
wild-type NPM1, such clones may promote the 
development of the myelodysplastic syndrome 
or primary myelofibrosis, especially in older pa-
tients. Did Ivey et al. obtain data that support 
this conclusion and, if so, did they observe an 
age-specific association?
Sarah Morin‑Zorman, M.D., Ph.D.
Hôpital Saint Louis 
Paris, France 
sarah . morin@ aphp . fr
The New England Journal of Medicine 
Downloaded from nejm.org at KINGS COLLEGE LONDON on December 14, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 375;6 nejm.org August 11, 2016e9(2)
Aline Renneville, M.D., Ph.D.
Centre Hospitalier Régional Universitaire de Lille 
Lille, France
Lionel Adès, M.D., Ph.D.
Hôpital Saint Louis 
Paris, France
No potential conflict of interest relevant to this letter was re-
ported.
DOI: 10.1056/NEJMc1603847
To the Editor: Ivey et al. report that the persis-
tence of NPM1-mutated transcripts in blood sam-
ples after two cycles of chemotherapy was associ-
ated with an increase by a factor of 6.8 in the risk 
of relapse (P<0.001) in patients with standard-
risk newly diagnosed AML. These findings and 
others1,2 suggest a potential role for monitoring 
measurable residual disease in patients with AML. 
However, to make these analyses useful to the 
physician for patient-level decision making, the 
data should be supplemented by a measure evalu-
ating patient-level prediction, such as a C-statistic. 
Our experience suggests that even for models 
that have several covariates with large hazard ra-
tios that are independently significant (at P<0.01), 
C-statistics often range from 0.75 to 0.80.3,4
Megan Othus, Ph.D.
Fred Hutchinson Cancer Research Center 
Seattle, WA 
mothus@ fhcrc . org
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Figure 1. Relapse or Progression of Acute Myeloid Leukemia (AML)  
and Evolution of the Variant Allele Frequency in Mutated Genes.
Panel A shows the cumulative incidence of relapse and evolution to the 
 myelodysplastic syndrome (MDS) or primary myelofibrosis (PMF) in 32 pa‑
tients with cytogenetically normal AML with the NPM1 mutation without 
internal tandem duplications in the gene encoding Fms‑like tyrosine kinase 3 
(FLT3‑ITD) during the first complete remission. (The presence of the NPM1 
mutation without the FLT3‑ITD genotype is associated with a better progno‑
sis.) Panel B shows the evolution of the variant allele frequency in mutated 
genes in 2 patients at the time of AML diagnosis and at the time of the diag‑
nosis of PMF (in Patient 1) or MDS (in Patient 2), with undetectable NPM1 
minimal residual disease.
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The authors reply: Baccarani asks whether the 
group of patients with delayed clearance of NPM1-
mutated transcripts could have been identified 
on the basis of a suboptimal morphological re-
sponse to induction therapy. We found that this 
was not the case. In the combined training and 
validation data sets involving 437 patients, 88% 
of patients who tested negative for NPM1-mutated 
transcripts in the peripheral blood and 89% of 
those who tested positive after two cycles of che-
motherapy had a complete remission with blood-
count recovery after the first cycle. We found no 
significant relationship between the response to 
the first cycle of chemotherapy and status with 
respect to minimal residual disease after the sec-
ond cycle; only 2 patients with evidence of mini-
mal residual disease in the peripheral blood after 
the second cycle had resistant disease after the 
first cycle, and 6% of patients without minimal 
residual disease and 4% of those with minimal 
residual disease had a partial remission after the 
first cycle. An analysis that was restricted to pa-
tients who would be expected to have the best 
prognosis (i.e., those who were in complete re-
mission after the first cycle of chemotherapy) 
showed a highly significant difference in survival 
according to whether NPM1-mutated transcripts 
were undetectable or detectable in peripheral blood 
after the second cycle of chemotherapy (75% and 
24%, respectively; P<0.001). These findings show 
that the status of minimal residual disease in pe-
ripheral blood after the second cycle of chemo-
therapy adds to the standard response criteria 
after the first cycle.
Othus and colleagues raise the issue of preci-
sion in predicting relapse. As with pretreatment 
variables,1 it is not realistic to expect that any 
minimal-residual-disease test that is applied at a 
single early time point during therapy will iden-
tify exactly which patients are destined to have 
a relapse after first-line therapy.2 However, this 
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Figure 1. Sequential Monitoring of Minimal Residual 
Disease and Relapse in AML.
Among 100 patients with NPM1‑mutated AML who were 
treated in the NCRI AML17 trial, who were tracked by 
means of real‑time quantitative polymerase‑chain‑reac‑
tion (RT‑qPCR) assay, and who were subject to disease 
recurrence, the NPM1‑mutated allele was stable at the 
time of relapse in 98 patients. In these patients, relapse 
was predicted by RT‑qPCR positivity, with a rising level 
of NPM1‑mutated transcripts, as exemplified in Patient 
17‑1792, whose data are shown in Panel A. Solid data 
points indicate that disease transcripts were detectable, 
and open data points indicate that they were undetect‑
able. For RT‑qPCR–negative samples, data points are 
plotted according to the maximal sensitivity afforded 
by the follow‑up sample. In 2 of 100 patients, the NPM1‑
mutated allele was not detected at the time of relapse. 
Data for the first of these patients were presented in 
our published report, and data for the second patient 
(number 17‑2772) are provided in Panel B. At diagno‑
sis, NPM1 and IDH1 mutations were detected. Both 
mutations persisted in the marrow after first‑line chemo‑
therapy. At 7 months after diagnosis, an increase in the 
NPM1‑mutated transcript level was detected, which 
was confirmed in a second sample confirming a diag‑
nosis of molecular relapse. The patient was treated pre‑
emptively with salvage chemotherapy, which eliminated 
the NPM1‑mutated clone; the patient subsequently had 
a relapse with IDH1‑mutated AML. The percentages at 
the top of the graph indicate the variant allele frequency 
for IDH1 R132G. In Panels A and B, the number of 
NPM1‑mutated copies has been normalized relative  
to the number of copies of the Abelson (ABL) control 
gene. FLAG denotes a regimen of fludarabine, high‑
dose cytarabine, and granulocyte colony‑stimulating 
factor, and Ida idarubicin.
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aspiration can be realized in the majority of 
patients through sequential monitoring of mini-
mal residual disease,2 as supported by our data 
(Fig. 1A). We found that the early assessment of 
minimal residual disease in patients with NPM1-
mutated AML provides a more powerful predictor 
of relapse risk than factors that are currently 
used to inform transplantation decisions3 in pa-
tients with AML. As such, we do not agree that 
the C-statistic is important in guiding treatment 
decisions. In our study, a naive application of the 
C-statistic to the pooled training and validation 
sets to predict mortality results in a value of 0.65. 
However, the C-statistic has limitations when 
applied to a binary marker, as described previ-
ously.4 There is little doubt that a marker that 
predicts 0% versus 75% survival would be worth 
knowing about and clinically relevant. Yet if this 
marker appears in only 10% of the population, 
the C-statistic is only 0.65. If it appeared in 50% 
of the population, the C-statistic would be 0.90. 
And yet the prognosis that is based on the 
marker is the same in both scenarios.
Morin-Zorman and colleagues describe an in-
teresting series of older adult patients with evi-
dence of preleukemic clones in which the NPM1-
mutated clone was eliminated by AML therapy 
but in whom myelodysplasia or myeloprolifera-
tive neoplasm subsequently developed. We agree 
that this phenomenon may be less common in 
younger patients, who were the focus of our 
study. Data on older patients are being collected 
in our ongoing “monitor versus no monitor” 
randomization on the basis of status regarding 
minimal residual disease in the NCRI AML17 
and AML19 trials. We have now extended our 
analysis of relapsed NPM1-mutated AML to 100 
patients (Fig. 1A), which showed the absence of 
the NPM1 mutation at relapse in 2 patients. We 
described the first patient in our published study. 
The clinical course of the second patient is pre-
sented in Figure 1B and serves to highlight the 
importance of studying multiple time points to 
fully understand the clonal dynamics underlying 
relapse.
Robert K. Hills, D.Phil.
Cardiff University School of Medicine 
Cardiff, United Kingdom
Adam Ivey, Ph.D.
Guy’s Hospital 
London, United Kingdom
David Grimwade, Ph.D.
King’s College London 
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david . grimwade@ kcl . ac . uk
for the UK National Cancer Research 
Institute (NCRI) AML Working Group
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